UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): September 1, 2015
| Blake Insomnia Therapeutics, Inc. |
| (Name of small business issuer in its charter) |
| Nevada | 2834 | 46-0780380 | ||
| (State or other Employer jurisdiction of Identification incorporation or organization) | (Primary Standard Industrial Classification Code Number) | (I.R.S. Number) |
Birger Jan Olsen
244, 5th Avenue, Suite A-154
New York, N.Y. 10001
Phone 1-646-513-2776
(Address and telephone number of registrant's principal executive offices and principal place of business)
Birger Jan Olsen
244, 5th Avenue, Suite A-154
New York, N.Y. 10001
Phone 1-646-513-2776
(Name, address, and telephone number of agent for service)
Jillian Ivey Sidoti, Esq
38730 Sky Canyon Drive – Ste A
Murrieta, CA 92563
PHONE 323-799-1342
jillian@syndicationlawyers.com
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
This Current Report on Form 8-K is filed by Blake Insomnia Therapeutics, Inc., a Nevada corporation, in connection with the items described below.
Item 8.01 Other Events.
The registrant’s new CUSIP number is 093152 106
Item 9.01 Financial Statement and Exhibits.
(d) EXHIBITS
None.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
| Blake Insomnia Therapeutics, Inc. |
| |
| Date: September 21, 2015 | By: | /s/ Birger Jan Olsen |
|
|
|
| Birger Jan Olsen |
|
|
|
| Chief Executive Officer |
|
3